September 24, 2021. Dr. Naveed Shams, chief scientific officer at ProQR, discusses RNA therapies and ProQR's three clinical trials targeting: Leber congenital amaurosis (a CEP290 mutation), USH2A exon 13, and retinitis pigmentosa (RHO-P23H).